Literature DB >> 30142439

TRPM4 mutations to cause autosomal recessive and not autosomal dominant Brugada type 1 syndrome.

Alexandre Janin1, Francis Bessière2, Tudor Georgescu3, Valérie Chanavat1, Philippe Chevalier2, Gilles Millat4.   

Abstract

Cardiac channelopathies, mainly Long QT and Brugada syndromes, are genetic disorders for which genotype/phenotypes relationships remains to be improved. To provide new insights into the Brugada syndrome pathophysiology, a mutational study was performed on a 64-year-old man presented with isolated exertional dyspnea (NYHA class: II-III), hypertension, chronic kidney disease, coronary disease, an electrocardiogram suggesting a Brugada type 1-like pattern with ST-segment elevation in leads V1-V2. Molecular diagnosis study was performed using molecular strategy based on the sequencing of a panel of 19 Brugada-associated genes. The proband was carrier of 2 TRPM4 null alleles [IVS9+1G > A and p. Trp525X] resulting in the absence of functional hTRPM4 proteins. Due to this unexpected genotype, meta-analysis of previously reported TRPM4 variations associated with cardiac pathologies was performed using ACMG guidelines. All were detected in a heterozygous status. This additional meta-analysis indicated that most of them could not be considered definitely as pathogen. In conclusion, our study reports, for the first time, identification of compound heterozygous TRPM4 null mutations in a proband with, at an arrhythmogenic level, only a Brugada type 1-like electrocardiogram. By combining the genotype/phenotype relationship of this case and analysis of previously reported TRPM4 variations, we suggest that loss-of-function TRPM4 variations, in a heterozygous status, could not be considered as pathogenic or likely pathogenic mutations in cardiac channelopathies such as Long QT syndrome or Brugada syndrome.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Arrhythmia disorders; Brugada syndrome; Cardiac channelopathies; Molecular diagnosis; TRPM4; Truncating mutations

Mesh:

Substances:

Year:  2018        PMID: 30142439     DOI: 10.1016/j.ejmg.2018.08.008

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  12 in total

1.  Novel SCN5A p.V1429M Variant Segregation in a Family with Brugada Syndrome.

Authors:  Michelle M Monasky; Emanuele Micaglio; Giuseppe Ciconte; Valeria Borrelli; Luigi Giannelli; Gabriele Vicedomini; Andrea Ghiroldi; Luigi Anastasia; Emanuela T Locati; Sara Benedetti; Chiara Di Resta; Giorgio Casari; Carlo Pappone
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

2.  Novel SCN5A p.W697X Nonsense Mutation Segregation in a Family with Brugada Syndrome.

Authors:  Emanuele Micaglio; Michelle M Monasky; Nicoletta Resta; Rosanna Bagnulo; Giuseppe Ciconte; Luigi Gianelli; Emanuela T Locati; Gabriele Vicedomini; Valeria Borrelli; Andrea Ghiroldi; Luigi Anastasia; Sara Benedetti; Chiara Di Resta; Maurizio Ferrari; Carlo Pappone
Journal:  Int J Mol Sci       Date:  2019-10-04       Impact factor: 5.923

3.  Evaluating the Use of Genetics in Brugada Syndrome Risk Stratification.

Authors:  Michelle M Monasky; Emanuele Micaglio; Emanuela T Locati; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-04-21

4.  Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants.

Authors:  Mel Lina Pinsach-Abuin; Bernat Del Olmo; Adrian Pérez-Agustin; Jesus Mates; Catarina Allegue; Anna Iglesias; Qi Ma; Daria Merkurjev; Sergiy Konovalov; Jing Zhang; Farah Sheikh; Amalio Telenti; Josep Brugada; Ramon Brugada; Melissa Gymrek; Julia di Iulio; Ivan Garcia-Bassets; Sara Pagans
Journal:  Cell Rep Med       Date:  2021-04-20

5.  Whole-Exome Sequencing Identifies a Novel TRPM4 Mutation in a Chinese Family with Atrioventricular Block.

Authors:  Yi Dong; Ran Du; Liang-Liang Fan; Jie-Yuan Jin; Hao Huang; Ya-Qin Chen; Dan-Dong Bi; Rong Xiang
Journal:  Biomed Res Int       Date:  2021-04-17       Impact factor: 3.411

6.  Hyperactivation of platelet-derived growth factor signalling contributes to arrhythmogenesis in Brugada syndrome.

Authors:  Hongkun Wang; Lizhen Xu; Shuai Han; Xiaochen Wang; Hao Wang; Jingjun Zhou; Jiaxi Shen; Zongkuai Yang; Luyang Yu; Zhouqing Huang; Tingyu Gong; Ming Qi; Fan Yang; Ping Liang
Journal:  Clin Transl Med       Date:  2022-02

7.  The Role of TRPM4 Gene Mutations in Causing Familial Progressive Cardiac Conduction Disease: A Further Contribution.

Authors:  Alberto Palladino; Andrea Antonio Papa; Roberta Petillo; Marianna Scutifero; Salvatore Morra; Luigia Passamano; Vincenzo Nigro; Luisa Politano
Journal:  Genes (Basel)       Date:  2022-01-28       Impact factor: 4.096

Review 8.  Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation.

Authors:  Oscar Campuzano; Georgia Sarquella-Brugada; Elena Arbelo; Sergi Cesar; Paloma Jordà; Alexandra Pérez-Serra; Rocío Toro; Josep Brugada; Ramon Brugada
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241

Review 9.  Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic?

Authors:  Oscar Campuzano; Georgia Sarquella-Brugada; Sergi Cesar; Elena Arbelo; Josep Brugada; Ramon Brugada
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

Review 10.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 2: TRPM4 in Health and Disease.

Authors:  Csaba Dienes; Zsigmond Máté Kovács; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.